Literature DB >> 12651595

Differential regulation of EphA2 in normal and malignant cells.

Jennifer Walker-Daniels1, Angela R Hess, Mary J C Hendrix, Michael S Kinch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12651595      PMCID： PMC1851246          DOI： 10.1016/S0002-9440(10)63899-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  73 in total

Review 1.  p53 and human cancer: the first ten thousand mutations.

Authors:  P Hainaut; M Hollstein
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation.

Authors:  H Miao; E Burnett; M Kinch; E Simon; B Wang
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

Review 3.  The genetics of hereditary melanoma and nevi. 1998 update.

Authors:  M H Greene
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

4.  Eph receptor-ligand interactions are necessary for guidance of retinal ganglion cell axons in vitro.

Authors:  T Ciossek; B Monschau; C Kremoser; J Löschinger; S Lang; B K Müller; F Bonhoeffer; U Drescher
Journal:  Eur J Neurosci       Date:  1998-05       Impact factor: 3.386

5.  The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization.

Authors:  D Stapleton; I Balan; T Pawson; F Sicheri
Journal:  Nat Struct Biol       Date:  1999-01

6.  PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor.

Authors:  B Hock; B Böhme; T Karn; T Yamamoto; K Kaibuchi; U Holtrich; S Holland; T Pawson; H Rübsamen-Waigmann; K Strebhardt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

7.  Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2.

Authors:  J P Himanen; M Henkemeyer; D B Nikolov
Journal:  Nature       Date:  1998-12-03       Impact factor: 49.962

8.  Oligomeric structure of the human EphB2 receptor SAM domain.

Authors:  C D Thanos; K E Goodwill; J U Bowie
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

9.  Overexpression of the EphA2 tyrosine kinase in prostate cancer.

Authors:  J Walker-Daniels; K Coffman; M Azimi; J S Rhim; D G Bostwick; P Snyder; B J Kerns; D J Waters; M S Kinch
Journal:  Prostate       Date:  1999-12-01       Impact factor: 4.104

10.  c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor.

Authors:  G Levkowitz; H Waterman; E Zamir; Z Kam; S Oved; W Y Langdon; L Beguinot; B Geiger; Y Yarden
Journal:  Genes Dev       Date:  1998-12-01       Impact factor: 11.361
View more
  56 in total

1.  The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus.

Authors:  Alexander S Hahn; Johanna K Kaufmann; Effi Wies; Elisabeth Naschberger; Julia Panteleev-Ivlev; Katharina Schmidt; Angela Holzer; Martin Schmidt; Jin Chen; Simone König; Armin Ensser; Jinjong Myoung; Norbert H Brockmeyer; Michael Stürzl; Bernhard Fleckenstein; Frank Neipel
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

Review 2.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

Review 3.  Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.

Authors:  Balázs Döme; Mary J C Hendrix; Sándor Paku; József Tóvári; József Tímár
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Regulation and misregulation of Eph/ephrin expression.

Authors:  Dina N Arvanitis; Alice Davy
Journal:  Cell Adh Migr       Date:  2012-03-01       Impact factor: 3.405

5.  Specificity of HCPTP variants toward EphA2 tyrosines by quantitative selected reaction monitoring.

Authors:  Deepa Balasubramaniam; Lake N Paul; Kristoff T Homan; Mark C Hall; Cynthia V Stauffacher
Journal:  Protein Sci       Date:  2011-05-23       Impact factor: 6.725

6.  Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

Authors:  Carla M Lema Tomé; Enzo Palma; Sara Ferluga; W Todd Lowther; Roy Hantgan; Jill Wykosky; Waldemar Debinski
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

Review 7.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

Review 8.  The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis.

Authors:  Irina Alho; Luís Costa; Manuel Bicho; Constança Coelho
Journal:  Tumour Biol       Date:  2013-04-14

9.  NMR studies of a heterotypic Sam-Sam domain association: the interaction between the lipid phosphatase Ship2 and the EphA2 receptor.

Authors:  Marilisa Leone; Jason Cellitti; Maurizio Pellecchia
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

10.  Capillary defects and exaggerated inflammatory response in the airways of EphA2-deficient mice.

Authors:  Tatsuma Okazaki; Amy Ni; Peter Baluk; Oluwasheyi A Ayeni; Jennifer Kearley; Anthony J Coyle; Alison Humbles; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.